# Low-Grade Inflammation in Musculoskeletal Disorders: Biological Basis and PRGF Role > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/low-grade-inflammation-musculoskeletal-disorders-prgf-role/ > **Published:** 2026-04-20T18:09:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:16:40-04:00 > **Clinical Summary:** Explore low-grade inflammation musculoskeletal disorders and the therapeutic role of PRGF in managing chronic inflammatory conditions effectively. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic PainInflammationMusculoskeletalOsteoarthritisPrp Journal Rehabilitacion Study Type Clinical Study Population Human participants Why This Matters This study highlights the shift from viewing common musculoskeletal conditions as purely degenerative to understanding them as inflammatory processes, opening new therapeutic pathways. The recognition that chronic low-grade inflammation drives conditions like osteoarthritis and tendinopathies fundamentally changes how we approach treatment selection and patient counseling. Clinical Summary This clinical study examines the biological basis of chronic low-intensity inflammation in musculoskeletal disorders including tendinopathies, osteoarthritis, and intervertebral disc disease. The authors investigate plasma rich in growth factors (PRGF), a specific leukocyte-free platelet-rich plasma preparation, as a therapeutic intervention targeting the inflammatory cascade. The study identifies the regenerative potential of platelet-derived proteins and the fibrin matrix as key therapeutic mechanisms. However, the authors acknowledge significant variability in clinical outcomes attributed to patient-specific pathophysiology, product inconsistencies, and diverse application protocols. Dr. Caplan’s Take “While the inflammatory paradigm for these conditions is compelling, I remain cautious about PRP therapies given the substantial variability in preparation methods and clinical protocols. The field needs standardized approaches before we can reliably predict which patients will benefit from these interventions.” Clinical Perspective 🧠 Clinicians should consider the inflammatory component when evaluating patients with chronic musculoskeletal pain, as this may inform both conventional anti-inflammatory strategies and emerging regenerative approaches. Patients interested in PRP or PRGF therapy should understand that outcomes remain unpredictable due to technical variations and individual biological factors. Standard evidence-based treatments should remain first-line until more standardized regenerative protocols emerge. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20%5BLow-grade%20inflammation%20in%20musculoskeletal%20disorders%3A%20biological%20basis%20and%20role%20...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/42001695/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/42001695/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20%5BLow-grade%20inflammation%20in%20musculoskeletal%20disorders%3A%20biological%20basis%20and%20role%20...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/42001695/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/42001695/](https://pubmed.ncbi.nlm.nih.gov/42001695/) Table of Contents - [FAQ](#FAQ)[What is PRGF and how does it differ from other PRP treatments?](#What_is_PRGF_and_how_does_it_differ_from_other_PRP_treatments) - [Which musculoskeletal conditions can benefit from PRGF therapy?](#Which_musculoskeletal_conditions_can_benefit_from_PRGF_therapy) - [What therapeutic effects does PRGF provide for musculoskeletal disorders?](#What_therapeutic_effects_does_PRGF_provide_for_musculoskeletal_disorders) - [Why do clinical outcomes with PRGF vary between patients?](#Why_do_clinical_outcomes_with_PRGF_vary_between_patients) - [How does the new understanding of inflammation change treatment approaches for “degenerative” conditions?](#How_does_the_new_understanding_of_inflammation_change_treatment_approaches_for_8220degenerative8221_conditions) - [Related](#Related) ## FAQ #### What is PRGF and how does it differ from other PRP treatments? PRGF (Plasma Rich in Growth Factors) is a specific type of platelet-rich plasma that contains no white blood cells and is activated with calcium chloride. Unlike other PRP preparations, PRGF’s leukocyte-free formulation may reduce inflammatory responses while maintaining regenerative benefits through platelet-derived proteins and the fibrin matrix. #### Which musculoskeletal conditions can benefit from PRGF therapy? PRGF shows promise for conditions involving chronic low-grade inflammation, including tendinopathies, osteoarthritis, and intervertebral disc disease. These conditions were previously considered purely degenerative but are now understood to involve inflammatory processes in structures like subchondral bone and vertebral endplates. #### What therapeutic effects does PRGF provide for musculoskeletal disorders? PRGF demonstrates multiple therapeutic properties including tissue repair, [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/), [immune system](https://cedclinic.com/fungal-contamination-cannabis-risks-arizona-preroll-recall/) modulation, pain relief, and anti-fibrotic activity. These effects work through the regenerative potential of platelet-derived proteins, plasma biomolecules, and the dynamic fibrin matrix system. #### Why do clinical outcomes with PRGF vary between patients? PRGF treatment outcomes vary due to individual patient pathophysiology, differences in product preparation and quality, and variations in application protocols. Patient-specific factors and treatment standardization significantly impact therapeutic effectiveness. #### How does the new understanding of inflammation change treatment approaches for “degenerative” conditions? Recognizing chronic low-intensity inflammation as a key mechanism shifts focus from purely symptomatic treatment to addressing underlying inflammatory processes. This approach targets previously overlooked structures like subchondral bone in osteoarthritis and vertebral endplates in disc disease, opening new therapeutic avenues. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis Use Linked to Reduced Inflammation-Related Proteins in People With HIV, Study Finds](https://cedclinic.com/cannabis-use-linked-to-reduced-inflammation-related-proteins-in-people-with-hiv-study-finds/) This study explores how [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may reduce inflammation-related proteins, offering insights relevant to inflammatory conditions. [Read More](https://cedclinic.com/cannabis-use-linked-to-reduced-inflammation-related-proteins-in-people-with-hiv-study-finds/) [Cannabinoids for Nerve Pain: What the Best Clinical Evidence Says About Sleep and Pain Relief](https://cedclinic.com/cannabinoid-therapy-neuropathic-pain-sleep-relief/) Review clinical evidence on cannabinoids for managing [neuropathic pain](https://cedclinic.com/cannabis-for-pain-relief/) and improving sleep, relevant to inflammation-related pain. [Explore Insights](https://cedclinic.com/cannabinoid-therapy-neuropathic-pain-sleep-relief/) [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) Discusses the complexities and considerations when combining opioids and [cannabis for pain management](https://cedclinic.com/medical-cannabis-patient-benefits/) in inflammatory conditions. [Learn More](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).